SHELTER.BO · BSE
SHELTER PHARMA LIMITED
₹38
+1.44% (+₹0.54)
Prev. close
₹37.46
Volume
9,000
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SHELTER PHARMA LIMITED
Shelter Pharma Limited manufactures and sells pharmaceutical products for human and animals in India. The company offers tablets, ointments, syrups, capsules, and oil for human health care; and mineral mixture for veterinary health care. It also provides OTC and ethical products. The company sells its products through distribution network, as well as exports its products. Shelter Pharma Limited was founded in 1965 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mustaqim Nisarahmed Sabugar
Headquarters
Ahmedabad
Employees
51
Website
shelter.co.inExchange
View on BSE ↗Key stats
Market cap
₹62.30 Cr
P/E ratio (TTM)
7.2
Dividend yield
1.02%
EPS (TTM)
₹5.16
Beta (1Y · daily vs NIFTY 50)
1.11
Beta (5Y · monthly vs NIFTY 50)
0.69
Shares float
1.01 Cr
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹36.15 Cr | ₹40.02 Cr | ₹50.66 Cr | ₹73.13 Cr | |
| EBITDA | — | ₹7.15 Cr | ₹8.58 Cr | ₹10.07 Cr | ₹12.74 Cr |
| — | ₹5.21 Cr | ₹6.20 Cr | ₹7.24 Cr | ₹9.03 Cr | |
| Diluted EPS | ₹1.59 | ₹4.49 | ₹5.36 | ₹6.26 | ₹5.16 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹21.45 Cr | ₹37.91 Cr | ₹48.34 Cr | ₹84.23 Cr | |
| ₹1.78 Cr | ₹57.73 L | ₹1.04 Cr | ₹80.10 L | |
| Stockholders' equity | ₹14.55 Cr | ₹35.81 Cr | ₹42.72 Cr | ₹76.63 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-96.38 L | ₹-1.96 Cr | ₹5.42 Cr | ₹-12.48 Cr | |
| Investing cash flow | — | ₹11.34 L | ₹-4.54 Cr | ₹-7.13 Cr | ₹-14.55 Cr |
| — | ₹27.89 L | ₹11.01 Cr | ₹8.53 L | ₹24.69 Cr | |
| Capital expenditure | — | ₹-41,000 | ₹-85.19 L | ₹-2.65 Cr | ₹-1.59 Cr |
| End cash position | — | ₹42.85 L | ₹5.04 Cr | ₹3.42 Cr | ₹1.08 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| SHELTER PHARMA LIMITED | ₹62.30 Cr | ₹37.46 | 7.2 | 0.81 | 11.8% | 0.01 | +44.4% | -16.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.